nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—MPO—Carboplatin—ovarian cancer	0.53	1	CbGbCtD
Nabumetone—PTGS2—ovarian follicle—ovarian cancer	0.0142	0.253	CbGeAlD
Nabumetone—PTGS1—oviduct—ovarian cancer	0.00654	0.116	CbGeAlD
Nabumetone—MPO—epithelium—ovarian cancer	0.00346	0.0615	CbGeAlD
Nabumetone—Melatonin—CYP1B1—ovarian cancer	0.0028	0.597	CrCbGaD
Nabumetone—MPO—bone marrow—ovarian cancer	0.00243	0.0431	CbGeAlD
Nabumetone—MPO—testis—ovarian cancer	0.00207	0.0369	CbGeAlD
Nabumetone—PTGS2—myometrium—ovarian cancer	0.002	0.0355	CbGeAlD
Nabumetone—PTGS2—embryo—ovarian cancer	0.00192	0.0342	CbGeAlD
Nabumetone—Melatonin—ESR1—ovarian cancer	0.00189	0.403	CrCbGaD
Nabumetone—PTGS1—epithelium—ovarian cancer	0.00164	0.0292	CbGeAlD
Nabumetone—PTGS1—uterine cervix—ovarian cancer	0.00163	0.0289	CbGeAlD
Nabumetone—PTGS2—epithelium—ovarian cancer	0.00157	0.0279	CbGeAlD
Nabumetone—PTGS2—uterine cervix—ovarian cancer	0.00156	0.0276	CbGeAlD
Nabumetone—MPO—lymph node—ovarian cancer	0.0015	0.0267	CbGeAlD
Nabumetone—PTGS1—endometrium—ovarian cancer	0.00147	0.0262	CbGeAlD
Nabumetone—PTGS2—endometrium—ovarian cancer	0.00141	0.025	CbGeAlD
Nabumetone—PTGS1—uterus—ovarian cancer	0.00136	0.0241	CbGeAlD
Nabumetone—PTGS2—uterus—ovarian cancer	0.0013	0.023	CbGeAlD
Nabumetone—PTGS1—female reproductive system—ovarian cancer	0.00122	0.0217	CbGeAlD
Nabumetone—PTGS2—female reproductive system—ovarian cancer	0.00117	0.0207	CbGeAlD
Nabumetone—PTGS1—female gonad—ovarian cancer	0.00111	0.0197	CbGeAlD
Nabumetone—PTGS1—vagina—ovarian cancer	0.0011	0.0196	CbGeAlD
Nabumetone—PTGS2—bone marrow—ovarian cancer	0.0011	0.0196	CbGeAlD
Nabumetone—PTGS2—female gonad—ovarian cancer	0.00106	0.0188	CbGeAlD
Nabumetone—PTGS2—vagina—ovarian cancer	0.00105	0.0187	CbGeAlD
Nabumetone—PTGS1—testis—ovarian cancer	0.000984	0.0175	CbGeAlD
Nabumetone—PTGS1—lymph node—ovarian cancer	0.000713	0.0127	CbGeAlD
Nabumetone—PTGS2—lymph node—ovarian cancer	0.000682	0.0121	CbGeAlD
Nabumetone—MPO—Selenium Micronutrient Network—SOD1—ovarian cancer	0.000677	0.0152	CbGpPWpGaD
Nabumetone—CYP1A2—Estrogen Receptor Pathway—CYP1B1—ovarian cancer	0.000644	0.0144	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IL2—ovarian cancer	0.000634	0.0142	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—SOD2—ovarian cancer	0.000609	0.0137	CbGpPWpGaD
Nabumetone—PTGS1—Overview of nanoparticle effects—PIK3CD—ovarian cancer	0.000553	0.0124	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—STAT3—ovarian cancer	0.000534	0.012	CbGpPWpGaD
Nabumetone—Vomiting—Topotecan—ovarian cancer	0.00052	0.00143	CcSEcCtD
Nabumetone—Malaise—Paclitaxel—ovarian cancer	0.00052	0.00143	CcSEcCtD
Nabumetone—Vertigo—Paclitaxel—ovarian cancer	0.000518	0.00142	CcSEcCtD
Nabumetone—Syncope—Paclitaxel—ovarian cancer	0.000517	0.00142	CcSEcCtD
Nabumetone—Leukopenia—Paclitaxel—ovarian cancer	0.000517	0.00142	CcSEcCtD
Nabumetone—Rash—Topotecan—ovarian cancer	0.000516	0.00141	CcSEcCtD
Nabumetone—Hypersensitivity—Vinorelbine—ovarian cancer	0.000516	0.00141	CcSEcCtD
Nabumetone—Dermatitis—Topotecan—ovarian cancer	0.000516	0.00141	CcSEcCtD
Nabumetone—Headache—Topotecan—ovarian cancer	0.000513	0.00141	CcSEcCtD
Nabumetone—Palpitations—Paclitaxel—ovarian cancer	0.00051	0.0014	CcSEcCtD
Nabumetone—Vomiting—Melphalan—ovarian cancer	0.00051	0.0014	CcSEcCtD
Nabumetone—Loss of consciousness—Paclitaxel—ovarian cancer	0.000507	0.00139	CcSEcCtD
Nabumetone—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.000507	0.00139	CcSEcCtD
Nabumetone—Liver function test abnormal—Epirubicin—ovarian cancer	0.000506	0.00139	CcSEcCtD
Nabumetone—Rash—Melphalan—ovarian cancer	0.000505	0.00139	CcSEcCtD
Nabumetone—Dermatitis—Melphalan—ovarian cancer	0.000505	0.00138	CcSEcCtD
Nabumetone—Chills—Docetaxel—ovarian cancer	0.000504	0.00138	CcSEcCtD
Nabumetone—Cough—Paclitaxel—ovarian cancer	0.000504	0.00138	CcSEcCtD
Nabumetone—Asthenia—Vinorelbine—ovarian cancer	0.000502	0.00138	CcSEcCtD
Nabumetone—Arrhythmia—Docetaxel—ovarian cancer	0.000502	0.00138	CcSEcCtD
Nabumetone—Hypokalaemia—Epirubicin—ovarian cancer	0.000499	0.00137	CcSEcCtD
Nabumetone—Hypertension—Paclitaxel—ovarian cancer	0.000498	0.00137	CcSEcCtD
Nabumetone—CYP1A2—Estrogen metabolism—CYP1B1—ovarian cancer	0.000497	0.0111	CbGpPWpGaD
Nabumetone—Alopecia—Docetaxel—ovarian cancer	0.000496	0.00136	CcSEcCtD
Nabumetone—Pruritus—Vinorelbine—ovarian cancer	0.000495	0.00136	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000493	0.00135	CcSEcCtD
Nabumetone—Anxiety—Paclitaxel—ovarian cancer	0.00049	0.00134	CcSEcCtD
Nabumetone—PTGS1—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000488	0.0109	CbGpPWpGaD
Nabumetone—Nausea—Topotecan—ovarian cancer	0.000486	0.00133	CcSEcCtD
Nabumetone—Discomfort—Paclitaxel—ovarian cancer	0.000485	0.00133	CcSEcCtD
Nabumetone—Gastritis—Epirubicin—ovarian cancer	0.000485	0.00133	CcSEcCtD
Nabumetone—Dry mouth—Paclitaxel—ovarian cancer	0.00048	0.00132	CcSEcCtD
Nabumetone—Diarrhoea—Vinorelbine—ovarian cancer	0.000479	0.00131	CcSEcCtD
Nabumetone—Nausea—Melphalan—ovarian cancer	0.000476	0.00131	CcSEcCtD
Nabumetone—Confusional state—Paclitaxel—ovarian cancer	0.000475	0.0013	CcSEcCtD
Nabumetone—Asthma—Epirubicin—ovarian cancer	0.000473	0.0013	CcSEcCtD
Nabumetone—Dysphagia—Epirubicin—ovarian cancer	0.000473	0.0013	CcSEcCtD
Nabumetone—Oedema—Paclitaxel—ovarian cancer	0.000471	0.00129	CcSEcCtD
Nabumetone—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000471	0.00129	CcSEcCtD
Nabumetone—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000468	0.00128	CcSEcCtD
Nabumetone—Pancreatitis—Epirubicin—ovarian cancer	0.000464	0.00127	CcSEcCtD
Nabumetone—Shock—Paclitaxel—ovarian cancer	0.000463	0.00127	CcSEcCtD
Nabumetone—Dizziness—Vinorelbine—ovarian cancer	0.000463	0.00127	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—CXCL8—ovarian cancer	0.000463	0.0104	CbGpPWpGaD
Nabumetone—Hypokalaemia—Doxorubicin—ovarian cancer	0.000461	0.00126	CcSEcCtD
Nabumetone—Angina pectoris—Epirubicin—ovarian cancer	0.000461	0.00126	CcSEcCtD
Nabumetone—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000461	0.00126	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000456	0.00125	CcSEcCtD
Nabumetone—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000455	0.00125	CcSEcCtD
Nabumetone—Anaemia—Docetaxel—ovarian cancer	0.000452	0.00124	CcSEcCtD
Nabumetone—Anorexia—Paclitaxel—ovarian cancer	0.000449	0.00123	CcSEcCtD
Nabumetone—Gastritis—Doxorubicin—ovarian cancer	0.000449	0.00123	CcSEcCtD
Nabumetone—Vomiting—Vinorelbine—ovarian cancer	0.000445	0.00122	CcSEcCtD
Nabumetone—Dysuria—Epirubicin—ovarian cancer	0.000443	0.00121	CcSEcCtD
Nabumetone—Rash—Vinorelbine—ovarian cancer	0.000441	0.00121	CcSEcCtD
Nabumetone—Dermatitis—Vinorelbine—ovarian cancer	0.000441	0.00121	CcSEcCtD
Nabumetone—CYP1A2—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000439	0.00984	CbGpPWpGaD
Nabumetone—PTGS2—Overview of nanoparticle effects—PIK3CD—ovarian cancer	0.000439	0.00983	CbGpPWpGaD
Nabumetone—Headache—Vinorelbine—ovarian cancer	0.000439	0.0012	CcSEcCtD
Nabumetone—Syncope—Docetaxel—ovarian cancer	0.000439	0.0012	CcSEcCtD
Nabumetone—Dysphagia—Doxorubicin—ovarian cancer	0.000438	0.0012	CcSEcCtD
Nabumetone—Asthma—Doxorubicin—ovarian cancer	0.000438	0.0012	CcSEcCtD
Nabumetone—Leukopenia—Docetaxel—ovarian cancer	0.000438	0.0012	CcSEcCtD
Nabumetone—Palpitations—Docetaxel—ovarian cancer	0.000432	0.00118	CcSEcCtD
Nabumetone—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000432	0.00118	CcSEcCtD
Nabumetone—Weight increased—Epirubicin—ovarian cancer	0.000431	0.00118	CcSEcCtD
Nabumetone—Loss of consciousness—Docetaxel—ovarian cancer	0.00043	0.00118	CcSEcCtD
Nabumetone—Pancreatitis—Doxorubicin—ovarian cancer	0.000429	0.00118	CcSEcCtD
Nabumetone—Weight decreased—Epirubicin—ovarian cancer	0.000428	0.00117	CcSEcCtD
Nabumetone—Hyperglycaemia—Epirubicin—ovarian cancer	0.000427	0.00117	CcSEcCtD
Nabumetone—Cough—Docetaxel—ovarian cancer	0.000427	0.00117	CcSEcCtD
Nabumetone—Angina pectoris—Doxorubicin—ovarian cancer	0.000427	0.00117	CcSEcCtD
Nabumetone—Insomnia—Paclitaxel—ovarian cancer	0.000426	0.00117	CcSEcCtD
Nabumetone—Pneumonia—Epirubicin—ovarian cancer	0.000425	0.00116	CcSEcCtD
Nabumetone—Paraesthesia—Paclitaxel—ovarian cancer	0.000423	0.00116	CcSEcCtD
Nabumetone—Hypertension—Docetaxel—ovarian cancer	0.000422	0.00116	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—PIK3CA—ovarian cancer	0.000421	0.00944	CbGpPWpGaD
Nabumetone—Dyspnoea—Paclitaxel—ovarian cancer	0.00042	0.00115	CcSEcCtD
Nabumetone—Somnolence—Paclitaxel—ovarian cancer	0.000419	0.00115	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000419	0.00115	CcSEcCtD
Nabumetone—Nausea—Vinorelbine—ovarian cancer	0.000416	0.00114	CcSEcCtD
Nabumetone—Renal failure—Epirubicin—ovarian cancer	0.000415	0.00114	CcSEcCtD
Nabumetone—Dyspepsia—Paclitaxel—ovarian cancer	0.000415	0.00114	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—ovarian cancer	0.000414	0.00929	CbGpPWpGaD
Nabumetone—Stomatitis—Epirubicin—ovarian cancer	0.000411	0.00113	CcSEcCtD
Nabumetone—Jaundice—Epirubicin—ovarian cancer	0.000411	0.00113	CcSEcCtD
Nabumetone—Dysuria—Doxorubicin—ovarian cancer	0.00041	0.00112	CcSEcCtD
Nabumetone—Decreased appetite—Paclitaxel—ovarian cancer	0.000409	0.00112	CcSEcCtD
Nabumetone—Dry mouth—Docetaxel—ovarian cancer	0.000407	0.00112	CcSEcCtD
Nabumetone—Fatigue—Paclitaxel—ovarian cancer	0.000406	0.00111	CcSEcCtD
Nabumetone—CYP1A2—Estrogen Receptor Pathway—ESR1—ovarian cancer	0.000405	0.00907	CbGpPWpGaD
Nabumetone—Constipation—Paclitaxel—ovarian cancer	0.000403	0.0011	CcSEcCtD
Nabumetone—Haematuria—Epirubicin—ovarian cancer	0.000402	0.0011	CcSEcCtD
Nabumetone—Confusional state—Docetaxel—ovarian cancer	0.000402	0.0011	CcSEcCtD
Nabumetone—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.0004	0.0011	CcSEcCtD
Nabumetone—Anaphylactic shock—Docetaxel—ovarian cancer	0.000399	0.00109	CcSEcCtD
Nabumetone—Oedema—Docetaxel—ovarian cancer	0.000399	0.00109	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—IL2—ovarian cancer	0.000399	0.00895	CbGpPWpGaD
Nabumetone—Weight increased—Doxorubicin—ovarian cancer	0.000399	0.00109	CcSEcCtD
Nabumetone—Weight decreased—Doxorubicin—ovarian cancer	0.000396	0.00109	CcSEcCtD
Nabumetone—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000395	0.00108	CcSEcCtD
Nabumetone—Agranulocytosis—Epirubicin—ovarian cancer	0.000394	0.00108	CcSEcCtD
Nabumetone—Pneumonia—Doxorubicin—ovarian cancer	0.000393	0.00108	CcSEcCtD
Nabumetone—Shock—Docetaxel—ovarian cancer	0.000393	0.00108	CcSEcCtD
Nabumetone—Thrombocytopenia—Docetaxel—ovarian cancer	0.000391	0.00107	CcSEcCtD
Nabumetone—Feeling abnormal—Paclitaxel—ovarian cancer	0.000388	0.00106	CcSEcCtD
Nabumetone—PTGS2—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000388	0.00869	CbGpPWpGaD
Nabumetone—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000387	0.00106	CcSEcCtD
Nabumetone—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000385	0.00106	CcSEcCtD
Nabumetone—Renal failure—Doxorubicin—ovarian cancer	0.000384	0.00105	CcSEcCtD
Nabumetone—Haemoglobin—Epirubicin—ovarian cancer	0.000381	0.00104	CcSEcCtD
Nabumetone—Stomatitis—Doxorubicin—ovarian cancer	0.000381	0.00104	CcSEcCtD
Nabumetone—Jaundice—Doxorubicin—ovarian cancer	0.000381	0.00104	CcSEcCtD
Nabumetone—Anorexia—Docetaxel—ovarian cancer	0.00038	0.00104	CcSEcCtD
Nabumetone—Haemorrhage—Epirubicin—ovarian cancer	0.000379	0.00104	CcSEcCtD
Nabumetone—Urticaria—Paclitaxel—ovarian cancer	0.000374	0.00103	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.000374	0.00838	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IL6—ovarian cancer	0.000373	0.00836	CbGpPWpGaD
Nabumetone—Haematuria—Doxorubicin—ovarian cancer	0.000372	0.00102	CcSEcCtD
Nabumetone—Abdominal pain—Paclitaxel—ovarian cancer	0.000372	0.00102	CcSEcCtD
Nabumetone—Body temperature increased—Paclitaxel—ovarian cancer	0.000372	0.00102	CcSEcCtD
Nabumetone—PTGS2—Overview of nanoparticle effects—CXCL8—ovarian cancer	0.000367	0.00824	CbGpPWpGaD
Nabumetone—Visual impairment—Epirubicin—ovarian cancer	0.000365	0.001	CcSEcCtD
Nabumetone—Agranulocytosis—Doxorubicin—ovarian cancer	0.000365	0.000999	CcSEcCtD
Nabumetone—Insomnia—Docetaxel—ovarian cancer	0.000361	0.00099	CcSEcCtD
Nabumetone—Paraesthesia—Docetaxel—ovarian cancer	0.000358	0.000983	CcSEcCtD
Nabumetone—Erythema multiforme—Epirubicin—ovarian cancer	0.000358	0.000982	CcSEcCtD
Nabumetone—Dyspnoea—Docetaxel—ovarian cancer	0.000356	0.000976	CcSEcCtD
Nabumetone—Somnolence—Docetaxel—ovarian cancer	0.000355	0.000973	CcSEcCtD
Nabumetone—Tinnitus—Epirubicin—ovarian cancer	0.000353	0.000969	CcSEcCtD
Nabumetone—Haemoglobin—Doxorubicin—ovarian cancer	0.000352	0.000966	CcSEcCtD
Nabumetone—Dyspepsia—Docetaxel—ovarian cancer	0.000351	0.000963	CcSEcCtD
Nabumetone—Haemorrhage—Doxorubicin—ovarian cancer	0.000351	0.000961	CcSEcCtD
Nabumetone—Decreased appetite—Docetaxel—ovarian cancer	0.000347	0.000951	CcSEcCtD
Nabumetone—Hypersensitivity—Paclitaxel—ovarian cancer	0.000347	0.000951	CcSEcCtD
Nabumetone—Fatigue—Docetaxel—ovarian cancer	0.000344	0.000944	CcSEcCtD
Nabumetone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—ovarian cancer	0.000342	0.00768	CbGpPWpGaD
Nabumetone—PTGS1—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000342	0.00767	CbGpPWpGaD
Nabumetone—Constipation—Docetaxel—ovarian cancer	0.000341	0.000936	CcSEcCtD
Nabumetone—Chills—Epirubicin—ovarian cancer	0.00034	0.000932	CcSEcCtD
Nabumetone—CYP1A2—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000339	0.0076	CbGpPWpGaD
Nabumetone—Arrhythmia—Epirubicin—ovarian cancer	0.000339	0.000928	CcSEcCtD
Nabumetone—Visual impairment—Doxorubicin—ovarian cancer	0.000338	0.000926	CcSEcCtD
Nabumetone—Asthenia—Paclitaxel—ovarian cancer	0.000338	0.000926	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—CDKN1B—ovarian cancer	0.000336	0.00754	CbGpPWpGaD
Nabumetone—Alopecia—Epirubicin—ovarian cancer	0.000335	0.000918	CcSEcCtD
Nabumetone—Pruritus—Paclitaxel—ovarian cancer	0.000333	0.000913	CcSEcCtD
Nabumetone—Erythema multiforme—Doxorubicin—ovarian cancer	0.000332	0.000909	CcSEcCtD
Nabumetone—Feeling abnormal—Docetaxel—ovarian cancer	0.000329	0.000902	CcSEcCtD
Nabumetone—Tinnitus—Doxorubicin—ovarian cancer	0.000327	0.000896	CcSEcCtD
Nabumetone—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000326	0.000895	CcSEcCtD
Nabumetone—Flatulence—Epirubicin—ovarian cancer	0.000325	0.000891	CcSEcCtD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—ovarian cancer	0.000324	0.00726	CbGpPWpGaD
Nabumetone—Tension—Epirubicin—ovarian cancer	0.000324	0.000888	CcSEcCtD
Nabumetone—Diarrhoea—Paclitaxel—ovarian cancer	0.000322	0.000883	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—CCND1—ovarian cancer	0.000321	0.00719	CbGpPWpGaD
Nabumetone—Nervousness—Epirubicin—ovarian cancer	0.00032	0.000878	CcSEcCtD
Nabumetone—Abdominal pain—Docetaxel—ovarian cancer	0.000316	0.000865	CcSEcCtD
Nabumetone—Body temperature increased—Docetaxel—ovarian cancer	0.000316	0.000865	CcSEcCtD
Nabumetone—Chills—Doxorubicin—ovarian cancer	0.000315	0.000863	CcSEcCtD
Nabumetone—Arrhythmia—Doxorubicin—ovarian cancer	0.000313	0.000859	CcSEcCtD
Nabumetone—Dizziness—Paclitaxel—ovarian cancer	0.000311	0.000854	CcSEcCtD
Nabumetone—Alopecia—Doxorubicin—ovarian cancer	0.00031	0.000849	CcSEcCtD
Nabumetone—Ill-defined disorder—Epirubicin—ovarian cancer	0.000306	0.000839	CcSEcCtD
Nabumetone—Anaemia—Epirubicin—ovarian cancer	0.000305	0.000836	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.000305	0.00683	CbGpPWpGaD
Nabumetone—Agitation—Epirubicin—ovarian cancer	0.000303	0.000831	CcSEcCtD
Nabumetone—Flatulence—Doxorubicin—ovarian cancer	0.000301	0.000825	CcSEcCtD
Nabumetone—Tension—Doxorubicin—ovarian cancer	0.0003	0.000821	CcSEcCtD
Nabumetone—Vomiting—Paclitaxel—ovarian cancer	0.000299	0.000821	CcSEcCtD
Nabumetone—PTGS2—S1P1 pathway—VEGFA—ovarian cancer	0.000298	0.00669	CbGpPWpGaD
Nabumetone—Malaise—Epirubicin—ovarian cancer	0.000297	0.000816	CcSEcCtD
Nabumetone—Rash—Paclitaxel—ovarian cancer	0.000297	0.000814	CcSEcCtD
Nabumetone—Dermatitis—Paclitaxel—ovarian cancer	0.000297	0.000813	CcSEcCtD
Nabumetone—Nervousness—Doxorubicin—ovarian cancer	0.000296	0.000813	CcSEcCtD
Nabumetone—Vertigo—Epirubicin—ovarian cancer	0.000296	0.000813	CcSEcCtD
Nabumetone—Syncope—Epirubicin—ovarian cancer	0.000296	0.000811	CcSEcCtD
Nabumetone—Leukopenia—Epirubicin—ovarian cancer	0.000295	0.00081	CcSEcCtD
Nabumetone—Headache—Paclitaxel—ovarian cancer	0.000295	0.000809	CcSEcCtD
Nabumetone—Hypersensitivity—Docetaxel—ovarian cancer	0.000294	0.000806	CcSEcCtD
Nabumetone—Palpitations—Epirubicin—ovarian cancer	0.000292	0.000799	CcSEcCtD
Nabumetone—Loss of consciousness—Epirubicin—ovarian cancer	0.00029	0.000795	CcSEcCtD
Nabumetone—MPO—Vitamin B12 Metabolism—IL6—ovarian cancer	0.000288	0.00646	CbGpPWpGaD
Nabumetone—Cough—Epirubicin—ovarian cancer	0.000288	0.000789	CcSEcCtD
Nabumetone—Asthenia—Docetaxel—ovarian cancer	0.000286	0.000785	CcSEcCtD
Nabumetone—Hypertension—Epirubicin—ovarian cancer	0.000285	0.000781	CcSEcCtD
Nabumetone—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000283	0.000776	CcSEcCtD
Nabumetone—Pruritus—Docetaxel—ovarian cancer	0.000282	0.000774	CcSEcCtD
Nabumetone—PTGS2—S1P1 pathway—MAPK3—ovarian cancer	0.000282	0.00633	CbGpPWpGaD
Nabumetone—Anaemia—Doxorubicin—ovarian cancer	0.000282	0.000773	CcSEcCtD
Nabumetone—Agitation—Doxorubicin—ovarian cancer	0.000281	0.000769	CcSEcCtD
Nabumetone—Anxiety—Epirubicin—ovarian cancer	0.00028	0.000767	CcSEcCtD
Nabumetone—Nausea—Paclitaxel—ovarian cancer	0.00028	0.000767	CcSEcCtD
Nabumetone—Discomfort—Epirubicin—ovarian cancer	0.000277	0.000761	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—SOD1—ovarian cancer	0.000277	0.00621	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—NRAS—ovarian cancer	0.000276	0.00619	CbGpPWpGaD
Nabumetone—Malaise—Doxorubicin—ovarian cancer	0.000275	0.000755	CcSEcCtD
Nabumetone—Dry mouth—Epirubicin—ovarian cancer	0.000275	0.000753	CcSEcCtD
Nabumetone—Vertigo—Doxorubicin—ovarian cancer	0.000274	0.000752	CcSEcCtD
Nabumetone—Syncope—Doxorubicin—ovarian cancer	0.000274	0.00075	CcSEcCtD
Nabumetone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—FASN—ovarian cancer	0.000273	0.00613	CbGpPWpGaD
Nabumetone—Leukopenia—Doxorubicin—ovarian cancer	0.000273	0.000749	CcSEcCtD
Nabumetone—Diarrhoea—Docetaxel—ovarian cancer	0.000273	0.000749	CcSEcCtD
Nabumetone—Confusional state—Epirubicin—ovarian cancer	0.000271	0.000744	CcSEcCtD
Nabumetone—Palpitations—Doxorubicin—ovarian cancer	0.00027	0.00074	CcSEcCtD
Nabumetone—Anaphylactic shock—Epirubicin—ovarian cancer	0.000269	0.000738	CcSEcCtD
Nabumetone—Oedema—Epirubicin—ovarian cancer	0.000269	0.000738	CcSEcCtD
Nabumetone—PTGS2—S1P1 pathway—MAPK1—ovarian cancer	0.000269	0.00602	CbGpPWpGaD
Nabumetone—Loss of consciousness—Doxorubicin—ovarian cancer	0.000268	0.000736	CcSEcCtD
Nabumetone—Cough—Doxorubicin—ovarian cancer	0.000266	0.00073	CcSEcCtD
Nabumetone—Shock—Epirubicin—ovarian cancer	0.000265	0.000726	CcSEcCtD
Nabumetone—Dizziness—Docetaxel—ovarian cancer	0.000264	0.000724	CcSEcCtD
Nabumetone—Thrombocytopenia—Epirubicin—ovarian cancer	0.000264	0.000723	CcSEcCtD
Nabumetone—Hypertension—Doxorubicin—ovarian cancer	0.000264	0.000723	CcSEcCtD
Nabumetone—Hyperhidrosis—Epirubicin—ovarian cancer	0.00026	0.000714	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	0.00026	0.00583	CbGpPWpGaD
Nabumetone—PTGS1—Overview of nanoparticle effects—IL6—ovarian cancer	0.00026	0.00583	CbGpPWpGaD
Nabumetone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—ovarian cancer	0.00026	0.00582	CbGpPWpGaD
Nabumetone—Anxiety—Doxorubicin—ovarian cancer	0.000259	0.00071	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—MYC—ovarian cancer	0.000257	0.00577	CbGpPWpGaD
Nabumetone—Discomfort—Doxorubicin—ovarian cancer	0.000257	0.000704	CcSEcCtD
Nabumetone—Anorexia—Epirubicin—ovarian cancer	0.000257	0.000704	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—TP53—ovarian cancer	0.000256	0.00575	CbGpPWpGaD
Nabumetone—Dry mouth—Doxorubicin—ovarian cancer	0.000254	0.000697	CcSEcCtD
Nabumetone—Vomiting—Docetaxel—ovarian cancer	0.000254	0.000696	CcSEcCtD
Nabumetone—Rash—Docetaxel—ovarian cancer	0.000252	0.00069	CcSEcCtD
Nabumetone—Dermatitis—Docetaxel—ovarian cancer	0.000251	0.000689	CcSEcCtD
Nabumetone—Confusional state—Doxorubicin—ovarian cancer	0.000251	0.000689	CcSEcCtD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—ovarian cancer	0.00025	0.00561	CbGpPWpGaD
Nabumetone—Headache—Docetaxel—ovarian cancer	0.00025	0.000686	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—SOD2—ovarian cancer	0.000249	0.00559	CbGpPWpGaD
Nabumetone—Oedema—Doxorubicin—ovarian cancer	0.000249	0.000683	CcSEcCtD
Nabumetone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000249	0.000683	CcSEcCtD
Nabumetone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000246	0.00551	CbGpPWpGaD
Nabumetone—Shock—Doxorubicin—ovarian cancer	0.000245	0.000672	CcSEcCtD
Nabumetone—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000244	0.000669	CcSEcCtD
Nabumetone—Insomnia—Epirubicin—ovarian cancer	0.000244	0.000668	CcSEcCtD
Nabumetone—Paraesthesia—Epirubicin—ovarian cancer	0.000242	0.000663	CcSEcCtD
Nabumetone—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000241	0.00066	CcSEcCtD
Nabumetone—Dyspnoea—Epirubicin—ovarian cancer	0.00024	0.000658	CcSEcCtD
Nabumetone—Somnolence—Epirubicin—ovarian cancer	0.000239	0.000656	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—KRAS—ovarian cancer	0.000238	0.00533	CbGpPWpGaD
Nabumetone—Anorexia—Doxorubicin—ovarian cancer	0.000237	0.000651	CcSEcCtD
Nabumetone—Nausea—Docetaxel—ovarian cancer	0.000237	0.00065	CcSEcCtD
Nabumetone—Dyspepsia—Epirubicin—ovarian cancer	0.000237	0.00065	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—IL6—ovarian cancer	0.000235	0.00526	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—ovarian cancer	0.000234	0.00526	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—ovarian cancer	0.000234	0.00526	CbGpPWpGaD
Nabumetone—CYP1A2—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000234	0.00526	CbGpPWpGaD
Nabumetone—Decreased appetite—Epirubicin—ovarian cancer	0.000234	0.000642	CcSEcCtD
Nabumetone—Fatigue—Epirubicin—ovarian cancer	0.000232	0.000636	CcSEcCtD
Nabumetone—Constipation—Epirubicin—ovarian cancer	0.00023	0.000631	CcSEcCtD
Nabumetone—CYP1A2—Estrogen Receptor Pathway—STAT3—ovarian cancer	0.000227	0.00508	CbGpPWpGaD
Nabumetone—Insomnia—Doxorubicin—ovarian cancer	0.000225	0.000618	CcSEcCtD
Nabumetone—Paraesthesia—Doxorubicin—ovarian cancer	0.000224	0.000613	CcSEcCtD
Nabumetone—Dyspnoea—Doxorubicin—ovarian cancer	0.000222	0.000609	CcSEcCtD
Nabumetone—Feeling abnormal—Epirubicin—ovarian cancer	0.000222	0.000608	CcSEcCtD
Nabumetone—Somnolence—Doxorubicin—ovarian cancer	0.000221	0.000607	CcSEcCtD
Nabumetone—Gastrointestinal pain—Epirubicin—ovarian cancer	0.00022	0.000604	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—SOD1—ovarian cancer	0.00022	0.00493	CbGpPWpGaD
Nabumetone—CYP1A2—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000219	0.00492	CbGpPWpGaD
Nabumetone—Dyspepsia—Doxorubicin—ovarian cancer	0.000219	0.000601	CcSEcCtD
Nabumetone—Decreased appetite—Doxorubicin—ovarian cancer	0.000217	0.000594	CcSEcCtD
Nabumetone—Fatigue—Doxorubicin—ovarian cancer	0.000215	0.000589	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—GADD45A—ovarian cancer	0.000214	0.0048	CbGpPWpGaD
Nabumetone—Urticaria—Epirubicin—ovarian cancer	0.000214	0.000586	CcSEcCtD
Nabumetone—Constipation—Doxorubicin—ovarian cancer	0.000213	0.000584	CcSEcCtD
Nabumetone—Abdominal pain—Epirubicin—ovarian cancer	0.000213	0.000584	CcSEcCtD
Nabumetone—Body temperature increased—Epirubicin—ovarian cancer	0.000213	0.000584	CcSEcCtD
Nabumetone—PTGS2—Overview of nanoparticle effects—IL6—ovarian cancer	0.000206	0.00463	CbGpPWpGaD
Nabumetone—Feeling abnormal—Doxorubicin—ovarian cancer	0.000205	0.000563	CcSEcCtD
Nabumetone—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000204	0.000558	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—HRAS—ovarian cancer	0.000202	0.00453	CbGpPWpGaD
Nabumetone—Hypersensitivity—Epirubicin—ovarian cancer	0.000198	0.000544	CcSEcCtD
Nabumetone—Urticaria—Doxorubicin—ovarian cancer	0.000198	0.000543	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—SOD2—ovarian cancer	0.000198	0.00444	CbGpPWpGaD
Nabumetone—Abdominal pain—Doxorubicin—ovarian cancer	0.000197	0.00054	CcSEcCtD
Nabumetone—Body temperature increased—Doxorubicin—ovarian cancer	0.000197	0.00054	CcSEcCtD
Nabumetone—Asthenia—Epirubicin—ovarian cancer	0.000193	0.00053	CcSEcCtD
Nabumetone—Pruritus—Epirubicin—ovarian cancer	0.00019	0.000522	CcSEcCtD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.00019	0.00425	CbGpPWpGaD
Nabumetone—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000187	0.00419	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—IL6—ovarian cancer	0.000186	0.00418	CbGpPWpGaD
Nabumetone—Diarrhoea—Epirubicin—ovarian cancer	0.000184	0.000505	CcSEcCtD
Nabumetone—Hypersensitivity—Doxorubicin—ovarian cancer	0.000184	0.000503	CcSEcCtD
Nabumetone—PTGS1—Biological oxidations—CYP1B1—ovarian cancer	0.000182	0.00407	CbGpPWpGaD
Nabumetone—Asthenia—Doxorubicin—ovarian cancer	0.000179	0.00049	CcSEcCtD
Nabumetone—Dizziness—Epirubicin—ovarian cancer	0.000178	0.000488	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	0.000177	0.00396	CbGpPWpGaD
Nabumetone—Pruritus—Doxorubicin—ovarian cancer	0.000176	0.000483	CcSEcCtD
Nabumetone—Vomiting—Epirubicin—ovarian cancer	0.000171	0.000469	CcSEcCtD
Nabumetone—Diarrhoea—Doxorubicin—ovarian cancer	0.00017	0.000467	CcSEcCtD
Nabumetone—Rash—Epirubicin—ovarian cancer	0.00017	0.000465	CcSEcCtD
Nabumetone—Dermatitis—Epirubicin—ovarian cancer	0.00017	0.000465	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—ovarian cancer	0.000169	0.0038	CbGpPWpGaD
Nabumetone—Headache—Epirubicin—ovarian cancer	0.000169	0.000462	CcSEcCtD
Nabumetone—Dizziness—Doxorubicin—ovarian cancer	0.000165	0.000452	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—ovarian cancer	0.000162	0.00364	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—ovarian cancer	0.000162	0.00363	CbGpPWpGaD
Nabumetone—Nausea—Epirubicin—ovarian cancer	0.00016	0.000438	CcSEcCtD
Nabumetone—Vomiting—Doxorubicin—ovarian cancer	0.000158	0.000434	CcSEcCtD
Nabumetone—Rash—Doxorubicin—ovarian cancer	0.000157	0.000431	CcSEcCtD
Nabumetone—Dermatitis—Doxorubicin—ovarian cancer	0.000157	0.00043	CcSEcCtD
Nabumetone—Headache—Doxorubicin—ovarian cancer	0.000156	0.000428	CcSEcCtD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000154	0.00345	CbGpPWpGaD
Nabumetone—Nausea—Doxorubicin—ovarian cancer	0.000148	0.000406	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	0.000147	0.0033	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	0.000147	0.0033	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000146	0.00327	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	0.000145	0.00326	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.00014	0.00314	CbGpPWpGaD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—ovarian cancer	0.000138	0.0031	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	0.000135	0.00303	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000133	0.00298	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	0.000132	0.00297	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	0.000132	0.00297	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TLR4—ovarian cancer	0.000126	0.00282	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	0.000125	0.0028	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000125	0.0028	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HSD17B6—ovarian cancer	0.000115	0.00257	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000113	0.00253	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000111	0.00249	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NME2—ovarian cancer	0.000111	0.00248	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—CDKN1B—ovarian cancer	0.000109	0.00245	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000109	0.00245	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000109	0.00245	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000107	0.00241	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	0.000106	0.00238	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—CCND1—ovarian cancer	0.000104	0.00234	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	0.0001	0.00224	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	0.0001	0.00224	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	9.79e-05	0.0022	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	9.4e-05	0.00211	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CHMP4C—ovarian cancer	9.18e-05	0.00206	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—NRAS—ovarian cancer	8.97e-05	0.00201	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NME2—ovarian cancer	8.8e-05	0.00197	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CXCL8—ovarian cancer	8.52e-05	0.00191	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—MYC—ovarian cancer	8.36e-05	0.00187	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	8.33e-05	0.00187	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CDKN1B—ovarian cancer	8.32e-05	0.00187	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	8.32e-05	0.00187	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	8.22e-05	0.00184	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	8.16e-05	0.00183	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CASP3—ovarian cancer	8.16e-05	0.00183	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IL2—ovarian cancer	8.15e-05	0.00183	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	8.05e-05	0.0018	CbGpPWpGaD
Nabumetone—PTGS2—Disease—BCL9—ovarian cancer	7.96e-05	0.00178	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CCND1—ovarian cancer	7.94e-05	0.00178	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	7.87e-05	0.00177	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—KRAS—ovarian cancer	7.72e-05	0.00173	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MMP9—ovarian cancer	7.71e-05	0.00173	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	7.66e-05	0.00172	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	7.66e-05	0.00172	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—IL6—ovarian cancer	7.63e-05	0.00171	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	7.49e-05	0.00168	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	7.49e-05	0.00168	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	7.49e-05	0.00168	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	7.46e-05	0.00167	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYTB—ovarian cancer	7.14e-05	0.0016	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	7.08e-05	0.00159	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	6.98e-05	0.00156	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—HRAS—ovarian cancer	6.57e-05	0.00147	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MAPK3—ovarian cancer	6.55e-05	0.00147	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MYC—ovarian cancer	6.37e-05	0.00143	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	6.29e-05	0.00141	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PPP1CC—ovarian cancer	6.24e-05	0.0014	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—BRIP1—ovarian cancer	6.24e-05	0.0014	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MAPK1—ovarian cancer	6.23e-05	0.0014	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—EGFR—ovarian cancer	6.23e-05	0.0014	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	6.11e-05	0.00137	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	6.08e-05	0.00136	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—IL6—ovarian cancer	6.05e-05	0.00136	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	6.02e-05	0.00135	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PPP1CC—ovarian cancer	5.92e-05	0.00133	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYTB—ovarian cancer	5.67e-05	0.00127	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	5.66e-05	0.00127	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	5.55e-05	0.00124	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	5.54e-05	0.00124	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	5.4e-05	0.00121	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	5.35e-05	0.0012	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TP53—ovarian cancer	5.23e-05	0.00117	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	5.21e-05	0.00117	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NME2—ovarian cancer	4.98e-05	0.00112	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—BRIP1—ovarian cancer	4.95e-05	0.00111	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PPP1CC—ovarian cancer	4.95e-05	0.00111	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IL6—ovarian cancer	4.79e-05	0.00107	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	4.71e-05	0.00106	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.55e-05	0.00102	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HDAC6—ovarian cancer	4.48e-05	0.00101	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	4.46e-05	0.000999	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	4.33e-05	0.000971	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	4.24e-05	0.00095	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	4.24e-05	0.00095	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	4.22e-05	0.000947	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—YAP1—ovarian cancer	4.19e-05	0.000938	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.14e-05	0.000929	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	4e-05	0.000898	CbGpPWpGaD
Nabumetone—PTGS2—Disease—XIAP—ovarian cancer	3.89e-05	0.000871	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SMARCA4—ovarian cancer	3.79e-05	0.000849	CbGpPWpGaD
Nabumetone—PTGS2—Disease—EREG—ovarian cancer	3.7e-05	0.000829	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	3.68e-05	0.000825	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.64e-05	0.000816	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.61e-05	0.000809	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	3.56e-05	0.000798	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.44e-05	0.000772	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—FASN—ovarian cancer	3.41e-05	0.000765	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—SLC5A5—ovarian cancer	3.36e-05	0.000752	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—YAP1—ovarian cancer	3.32e-05	0.000745	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.29e-05	0.000737	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—SLC2A1—ovarian cancer	3.24e-05	0.000727	CbGpPWpGaD
Nabumetone—PTGS2—Disease—FASN—ovarian cancer	3.23e-05	0.000725	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PARP1—ovarian cancer	3.22e-05	0.000722	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYTB—ovarian cancer	3.21e-05	0.000719	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.17e-05	0.000712	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.13e-05	0.000703	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP1B1—ovarian cancer	3.11e-05	0.000697	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SLC2A1—ovarian cancer	3.07e-05	0.000689	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	3e-05	0.000674	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.89e-05	0.000648	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—BRIP1—ovarian cancer	2.8e-05	0.000628	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PPP1CC—ovarian cancer	2.8e-05	0.000628	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PPP2R1A—ovarian cancer	2.76e-05	0.000618	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.74e-05	0.000615	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—FASN—ovarian cancer	2.71e-05	0.000607	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SLC5A5—ovarian cancer	2.66e-05	0.000597	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PPP2R1A—ovarian cancer	2.61e-05	0.000586	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SLC2A1—ovarian cancer	2.57e-05	0.000577	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ABCB1—ovarian cancer	2.56e-05	0.000574	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.52e-05	0.000565	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—TYMS—ovarian cancer	2.51e-05	0.000563	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP1B1—ovarian cancer	2.47e-05	0.000553	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PPP2R1A—ovarian cancer	2.19e-05	0.00049	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.18e-05	0.000488	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TERT—ovarian cancer	2.08e-05	0.000465	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.04e-05	0.000458	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ABCB1—ovarian cancer	2.03e-05	0.000455	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CAV1—ovarian cancer	2.03e-05	0.000454	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—TYMS—ovarian cancer	2e-05	0.000447	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.93e-05	0.000434	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CAV1—ovarian cancer	1.92e-05	0.00043	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—YAP1—ovarian cancer	1.88e-05	0.000422	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.86e-05	0.000417	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CG—ovarian cancer	1.84e-05	0.000414	CbGpPWpGaD
Nabumetone—PTGS2—Disease—IL6ST—ovarian cancer	1.82e-05	0.000408	CbGpPWpGaD
Nabumetone—PTGS2—Disease—APC—ovarian cancer	1.75e-05	0.000392	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.64e-05	0.000367	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CD—ovarian cancer	1.62e-05	0.000364	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CAV1—ovarian cancer	1.61e-05	0.00036	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PIK3CD—ovarian cancer	1.54e-05	0.000345	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.54e-05	0.000344	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—FASN—ovarian cancer	1.53e-05	0.000344	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1.51e-05	0.000338	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CG—ovarian cancer	1.46e-05	0.000328	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SLC2A1—ovarian cancer	1.46e-05	0.000326	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.43e-05	0.00032	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CB—ovarian cancer	1.41e-05	0.000317	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP1B1—ovarian cancer	1.4e-05	0.000313	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ERBB2—ovarian cancer	1.36e-05	0.000304	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MTOR—ovarian cancer	1.34e-05	0.0003	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PIK3CB—ovarian cancer	1.34e-05	0.0003	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CD—ovarian cancer	1.29e-05	0.000289	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CDKN1B—ovarian cancer	1.26e-05	0.000282	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.24e-05	0.000278	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.23e-05	0.000276	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTEN—ovarian cancer	1.22e-05	0.000274	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CTNNB1—ovarian cancer	1.19e-05	0.000266	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PTEN—ovarian cancer	1.16e-05	0.00026	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.15e-05	0.000258	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TYMS—ovarian cancer	1.13e-05	0.000253	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CB—ovarian cancer	1.12e-05	0.000252	CbGpPWpGaD
Nabumetone—PTGS2—Disease—STAT3—ovarian cancer	1.04e-05	0.000232	CbGpPWpGaD
Nabumetone—PTGS2—Disease—NRAS—ovarian cancer	1.03e-05	0.000232	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MAPK3—ovarian cancer	9.89e-06	0.000222	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PTEN—ovarian cancer	9.7e-06	0.000217	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MYC—ovarian cancer	9.62e-06	0.000216	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MAPK1—ovarian cancer	9.41e-06	0.000211	CbGpPWpGaD
Nabumetone—PTGS2—Disease—EGFR—ovarian cancer	9.41e-06	0.000211	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CAV1—ovarian cancer	9.1e-06	0.000204	CbGpPWpGaD
Nabumetone—PTGS2—Disease—KRAS—ovarian cancer	8.89e-06	0.000199	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	8.69e-06	0.000195	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CA—ovarian cancer	8.62e-06	0.000193	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CG—ovarian cancer	8.29e-06	0.000186	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PIK3CA—ovarian cancer	8.17e-06	0.000183	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HRAS—ovarian cancer	7.56e-06	0.000169	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CD—ovarian cancer	7.29e-06	0.000163	CbGpPWpGaD
Nabumetone—PTGS2—Disease—IL6—ovarian cancer	7.23e-06	0.000162	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—AKT1—ovarian cancer	7.04e-06	0.000158	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CA—ovarian cancer	6.84e-06	0.000153	CbGpPWpGaD
Nabumetone—PTGS2—Disease—AKT1—ovarian cancer	6.67e-06	0.00015	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CB—ovarian cancer	6.35e-06	0.000142	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—AKT1—ovarian cancer	5.59e-06	0.000125	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTEN—ovarian cancer	5.49e-06	0.000123	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CA—ovarian cancer	3.87e-06	8.68e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—AKT1—ovarian cancer	3.16e-06	7.09e-05	CbGpPWpGaD
